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The work of Kumar and Wigge puts 
down a long-awaited cornerstone upon 
which to build an understanding of ambi-
ent temperature sensing by plants. The 
signaling networks regulating tempera-
ture-mediated physiological responses 
are likely to be complex and involve 
modulation by other environmental 
cues. Molecular dissection of such intri-
cate networks presents a daunting chal-
lenge for the future but will be essential 
for enhancing our understanding of how 
plants grow and develop in fluctuating 
natural environments.
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The re-emergence of the field of tumor 
cell metabolism has yielded important 
new insights into the metabolic repro-
gramming of cells that accompanies their 
oncogenic transformation (for recent 
reviews, see Hsu and Sabatini, 2008; 
Vander Heiden et al., 2009). The funda-
mental differences in both the catabolic 
and anabolic properties of a tumor cell 
relative to its tissue of origin could pro-
vide opportunities for new selective ther-
apeutic approaches. How cancer cells 
sense and use nutrients also impacts our 
understanding of dietary influences on 
tumor development and progression. To 
date, the majority of research on cancer 
metabolism has focused on the nearly 
ubiquitous catabolic switch of tumor 
cells (and other rapidly proliferating cells) 
from oxidative to glycolytic metabolism 
even in the presence of oxygen. This is 
referred to as aerobic glycolysis or, more 
popularly, the Warburg effect. However, 
tumor cells also commandeer anabolic 
processes resulting in elevated rates of 
protein, nucleic acid, and lipid biosyn-
thesis. For instance, tumor cells exhibit 
a pronounced increase in de novo fatty 
acid synthesis, whereas normal cells are 
thought to acquire fatty acids primarily 
from dietary sources (Medes et al., 1953; 
Menendez and Lupu, 2007). In this issue 
of Cell, Nomura et al. (2010) demonstrate 
an unexpected role for lipolytic remodel-
ing of lipid species in promoting the tum-
origenic properties of cancer cells.
A functional screen for differences 
in the activity of serine hydrolases in a 
small number of human cancer cell lines 
revealed that the activity of monoacyl-
glycerol lipase (MAGL) was elevated in 
those lines classified as more aggressive 
(Nomura et al., 2010). MAGL activity was 
also elevated in ovarian tumor tissue from 
patients with more advanced disease. 
This enzyme hydrolyzes monoacylglycer-
ols (MAGs) to release glycerol and a free 
fatty acid (FFA), and its best-character-
ized substrate is 2-arachidonoylglycerol, 
an endocannabinoid MAG (Long et al., 
2009). Interestingly, the more aggressive 
cancer cell lines and high-grade primary 
tumors contained elevated FFA levels, 
which could be substantially reduced by 
pharmacological and short-hairpin RNA-
mediated attenuation of MAGL activity. 
This surprising finding suggests that 
MAGL-dependent hydrolysis of MAGs 
is a major source of intracellular FFAs in 
aggressive cancer cells.
The MAGL-dependent remodeling of 
lipids appears to contribute to the trans-
formed properties of tumor cells (Nomura 
et al., 2010). Using in vitro cell-based 
assays, the authors found that inhibition 
of MAGL activity impaired the enhanced 
migration and invasive capabilities of 
aggressive cancer cells and diminished 
their survival upon growth factor with-
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Tumor cells undergo a metabolic shift toward specific bioenergetic (glycolysis) and anabolic (protein 
and lipid synthesis) processes that promote rapid growth. Nomura et al. (2010) now demonstrate 
that an increase in monoacylglycerol lipase (MAGL) drives tumorigenesis through the lipolytic 
release and remodeling of free fatty acids.
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drawal. Interestingly, exogenous addi-
tion of the saturated FFAs palmitate 
(C16) or stearate (C18) to MAGL-inhibited 
cells rescued the migration defects. 
Reciprocally, overexpression of MAGL 
or addition of FFAs could enhance these 
phenotypes in less aggressive cancer 
cell lines exhibiting low MAGL activity. 
MAGL knockdown or pharmacological 
inhibition also blunted xenograft tumor 
growth in mice, and this was accompa-
nied by a significant decrease in FFA lev-
els within the tumors. Strikingly, these in 
vivo effects of MAGL inhibition on tumor 
growth and lipid levels were reversed by 
feeding the mice a high-fat diet. Collec-
tively, these data demonstrate that MAGL 
promotes the oncogenic properties of 
tumor cells by increasing FFA levels.
To determine the mechanism of action 
of the FFA products of MAGL activ-
ity, the investigators took a lipidomics 
approach to identify lipid species sensi-
tive to increases or decreases in MAGL 
activity in cancer cells (Nomura et al., 
2010). This profile revealed that MAGL 
activity not only decreases MAGs and 
increases FFAs, but it also leads to an 
increase in specific FFA-derived signal-
ing lipids, such as phosphatidic acid 
(PA), lysophosphatidic acid (LPA), and 
prostaglandin E2 (PGE2) (Figure 1). The 
authors propose that these lipids acti-
vate tumor-promoting signaling events, 
and they demonstrate that LPA and 
PGE2 can rescue the migration defects 
of cancer cells with attenuated MAGL 
activity. Interestingly, both LPA and PGE2 
stimulate G protein-coupled receptor-
mediated signaling events and promote 
multiple oncogenic properties in tumor 
cells (Dorsam and Gutkind, 2007). This 
study suggests that MAGL activity plays 
a major role in the production of signal-
ing lipids, which then stimulate tumor 
cells in an autocrine manner.
The relationship between the synthesis, 
storage, and use of FFAs in tumor cells 
is poorly understood. Most cancer cells 
express elevated levels of fatty acid syn-
thase, a multifunctional enzyme that con-
verts malonyl CoA to palmitate, thereby 
explaining the increase in de novo lipo-
genesis in these cells (Medes et al., 1953; 
Menendez and Lupu, 2007). However, 
the Nomura et al. study makes a compel-
ling case that hydrolysis of acylglycerols, 
such as MAG, is a major source of FFAs 
in tumor cells (Figure 1). The authors pro-
pose that newly synthesized FFAs are 
immediately converted into neutral lipid 
stores and that the use of FFAs is depen-
dent on their lipolytic release, with MAGL 
being the critical lipase. However, further 
investigation regarding the fate of newly 
synthesized FFAs versus those released 
by hydrolysis of acylglycerols in tumor 
cells is needed. Through in vitro assays, 
Nomura et al. focus primarily on the con-
tribution of MAGL-derived lipid media-
tors to cancer cell migration. However, 
the tumor-promoting effects of MAGL in 
the in vivo xenograft mouse model are 
more likely to depend on increased cell 
growth and proliferation. The latter are 
predicted to rely on lipid remodeling for 
new membrane biosynthesis and, per-
haps, β-oxidation for energy production 
to support accompanying anabolic pro-
cesses. Although the bioenergetic needs 
of cancer cells are predominantly met 
through glycolysis, the oxidation of FFAs 
offers an alternative route (e.g., Buzzai 
et al., 2005; Schafer et al., 2009). Again, 
the question is whether the in vivo fates 
of FFAs derived from de novo synthesis 
versus lipolytic release differ or whether 
FFAs ultimately enter the same pool for 
remodeling or catabolic use.
Many exciting new questions arise from 
the findings reported by Nomura and col-
leagues regarding the role of both MAGL 
and exogenous lipids in tumor develop-
ment and progression. For instance, how 
are MAGL expression and activity regu-
lated in tumor cells, and how widespread 
is its activation in cancer? Is MAGL a 
metastasis factor and can its activity be 
used as a biomarker to predict the influ-
ence of dietary fats and obesity on tumor 
progression? Although MAGL was found 
to increase cell migration and invasion 
in vitro, the effects on tumor metastasis 
were not examined in the Nomura et al. 
study. Interestingly, the inhibitory effects 
of MAGL attenuation on tumor growth 
were reversed by feeding the mice a 
high-fat diet, which has been shown to 
promote metastasis in other xenograft 
tumor models (e.g., Rose et al., 1991). It 
will be interesting to determine whether 
conditions of obesity lead to increased 
figure 1. free fatty Acids and Tumorigenesis
Tumor cells display elevated rates of de novo free fatty acid (FFA) synthesis due, in large part, to increased 
expression of fatty acid synthase. Newly synthesized FFAs are believed to be converted to neutral lipid 
stores, including mono-, di-, or triacylglycerols. The activity of monoacylglycerol lipase (MAGL), which 
catalyzes the lipolytic release of FFAs from monoacylglycerols (MAGs), is elevated in more aggressive 
tumor cells (Nomura et al., 2010). MAGL plays a critical role in maintaining the increase in FFAs in such 
cells and in promoting the production of FFA-derived signaling lipids, such as phosphatidic acid (PA), 
lysophosphatidic acid (LPA), and prostaglandin E2 (PGE2). Other potential fates of newly synthesized or 
released FFAs include conversion to specific lipid species for incorporation into cellular membranes or 
β-oxidation for the production of ATP. FFA remodeling and utilization contribute to tumor cell proliferation, 
growth, and migration.
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levels of FFA-derived signaling lipids, 
such as LPA, within tumors. Finally, the 
antitumor effects of the MAGL-selective 
inhibitor used in this study suggest that 
MAGL is a promising therapeutic target 
for treating cancer. However, the critical 
role of MAGL in attenuating endocan-
nabinoid signaling in the brain could lead 
to behavioral side effects that are unique 
among cancer drugs (Long et al., 2009). 
It is clear that we are just beginning to 
understand the molecular contributions 
of alterations in lipid metabolism to can-
cer pathogenesis.
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The formation of the nervous system is 
a complex process that requires func-
tional microtubules during all stages of 
development. Events such as neurogen-
esis, neuronal migration, axon pathfind-
ing, and synapse formation are regulated 
by intrinsic and extrinsic pathways that 
ultimately impinge on the microtubule 
network, which carries out the structural 
changes that underlie each process. 
However, it is only recently that muta-
tions have been discovered in human 
genes encoding tubulin, the monomer 
that polymerizes into microtubules. 
Mutations in human genes such as 
TUB1A1 and TUBB2B, which encode 
α-tubulin and β-tubulin, respectively, or 
in genes that regulate microtubule func-
tion such as Lis1 and Doublecortin (Dcx) 
(des Portes et al., 1998; Gleeson et al., 
1998; Jaglin et al., 2009; Keays et al., 
2007; Poirier et al., 2007) give rise to dis-
orders of brain development. Such disor-
ders are characterized by lissencephaly 
(lack of brain folds) and polymicrogyria 
(excessive brain convolutions), which 
are caused principally by dysfunctional 
neuronal migration. In this issue of Cell, 
Tischfield et al. (2010) add to this grow-
ing literature with their report of new 
mutations in the human TUBB3 gene 
encoding neuronal βIII-tubulin. Using a 
multidisciplinary approach, they uncover 
TUBB3 mutations that produce diverse 
clinical phenotypes including ocular 
motility disorder (CFEOM3). Surprisingly, 
this is due primarily to disrupted axon 
guidance and not dysfunctional neuronal 
migration. This study elegantly examines 
the relationship among TUBB3 muta-
tions, their impact on microtubule func-
tion, and clinical symptoms.
Using a family-based approach, the 
authors identified eight heterozygous 
mutations in TUBB3. Clinically, the 
authors discovered that patients with the 
R262C mutation (the most commonly 
mutated residue) or the D417N mutation 
display hypoplasia of the ocular motor 
nerve and of several other nerve tracts, 
indicating defects in axon guidance and 
maintenance. Equally interesting is their 
observation that patients harboring dif-
ferent mutations in TUBB3 display a vari-
ety of clinical diagnoses. Although most 
patients suffer from CFEOM3, those 
with R262H, E410K, or D417H mutations 
also possess varying degrees of facial 
paralysis and progressive sensorimo-
tor polyneuropathy. This led the authors 
to speculate that a genotype-phenotype 
relationship exists, where a specific muta-
tion is associated with a particular set of 
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The microtubule network is crucial for the developing nervous system, and mutations in tubulin-
encoding genes disrupt neuronal migration. Tischfield et al. (2010) now report that mutations in 
the tubulin-encoding gene TUBB3 have a striking impact on microtubule dynamics in neurons, 
resulting in a diverse set of disease symptoms.
